Hyperpolarized 13C MRI As a Biomarker in Advanced Solid Tumors

Eligibility Criteria

• 1. Presence of at least one target pelvic, abdominal, thoracic, neck or extremity lesion detected by standard staging scans that, in the judgment of study investigator, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging:
• 2. The participant is able and willing to comply with study procedures and provide signed and dated informed consent.
• 3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• 4. Adequate renal function defined as creatinine \< 1.5 x upper limit of normal (ULN) or estimated creatinine clearance \>50 mL/min (by the Cockcroft Gault equation).
• 5. Participants age 18 and older.
• 6. Planned treatment for disease with either standard of care regimen or an investigational agent.
• 1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.
• 2. Patients with contra- indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.
• 3. Patients with a metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging.
• 4. Patients with poorly controlled hypertension, defined as systolic blood pressure at study entry greater than 160mm Hg or diastolic blood pressure greater than 100mm Hg.
• 5. Patients with congestive heart failure or New York Heart Association (NYHA) status \>= 2.
• 6. Patients who are pregnant or lactating.
• 7. A history of clinically significant EKG abnormalities or myocardial infarction (MI) within 6 months of study entry.
• 8. Any condition that, in the opinion of the Principal Investigator,